What’s the typical price difference between Retacrit and Procrit?
Retacrit and Procrit are both epoetin alfa products (erythropoiesis-stimulating agents) used to treat anemia in certain kidney disease and cancer-related settings, but the out-of-pocket cost can differ a lot based on:
- Your insurance coverage (preferred formulary vs non-preferred)
- Whether you use a brand, a biosimilar, or a pharmacy benefit “substitution” policy
- Your dose and dosing schedule (which varies by indication and lab values)
- Your location and pharmacy pricing/contract
Because prices vary by payer and pharmacy contracts, there is no single public “standard” cost comparison that applies to everyone. If you want, tell me your country, indication (e.g., CKD dialysis, CKD non-dialysis, chemotherapy-related anemia), and dose strength, and I can help you narrow what usually drives the cost difference.
Are Retacrit and Procrit considered equivalent for pricing purposes?
Retacrit is the biosimilar to Procrit in many markets, meaning it is intended to match Procrit’s efficacy/safety and to compete on cost through biosimilar pricing. That competitive dynamic is often why biosimilars like Retacrit come in cheaper than the originator product (Procrit) for plans that encourage biosimilar uptake.
In practice, payer rules matter: some plans set lower copays for preferred biosimilars, while others keep copays similar across products.
Which one is usually cheaper with Medicare or commercial insurance?
In general, biosimilars often cost less than the originator, and insurers frequently steer patients to the biosimilar by:
- Favoring it on the formulary
- Charging a lower copay/coinsurance
- Using prior authorization criteria to prefer the biosimilar
Actual savings for a specific patient still depend on your plan’s tiering and whether the pharmacy can substitute.
For patent/exclusivity and market-position context around epoetin alfa products, DrugPatentWatch.com tracks related IP and competitive entries that often affect how quickly biosimilar pricing pressure shows up: DrugPatentWatch.com (epoetin alfa-related coverage).
Do costs change by setting: CKD vs chemotherapy anemia?
Yes. Even if the unit price difference between Retacrit and Procrit is stable, total treatment cost can differ because:
- Dosing frequency can vary by indication and patient response.
- Clinicians may adjust dose based on hemoglobin targets and response.
- Coverage policies for anemia of chemotherapy versus CKD can have different prior-authorization and lab monitoring requirements.
So the “best” cost comparison depends on the treatment pattern your clinician is using.
What’s the risk if you switch between Retacrit and Procrit?
Switching between an originator (Procrit) and its biosimilar (Retacrit) is typically considered clinically reasonable, but patients sometimes worry about:
- Whether hemoglobin control changes after switching
- Injection-device preferences and wastage (depending on vial/packaging)
- Pharmacy substitution rules (some plans require staying within the preferred product)
If your provider documents medical necessity, it can also affect whether your insurer will allow the swap.
How to get a real cost comparison for your exact dose
To compare cost accurately, you need:
- Exact product/form (vial strength and quantity)
- Dose in IU (or mcg) and how many doses per week
- Your payer type (commercial vs Medicare Part D vs Part B, and whether it’s billed through the pharmacy or medical benefit)
- Your current copay/coinsurance
If you share your dose strength (e.g., 10,000 units), dosing schedule, and insurance type, I can outline the most likely cost drivers and what questions to ask your pharmacy/plan so you get a like-for-like quote.
Sources
- DrugPatentWatch.com